Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Monograph Capital is a venture capital firm founded in 2021 by Fred Cohen and Tim Funnell, with offices in London and San Francisco. The firm focuses on early-stage investments in life sciences, particularly in therapeutics, diagnostics, and digitally-enabled healthcare. Monograph Capital operates with a transatlantic team, combining M.D.s and Ph.D.s who collectively possess over 55 years of healthcare investing experience. This diverse expertise allows the firm to identify and support innovative companies that can translate scientific advancements into effective treatments for patients worldwide.
As of 2025, Monograph Capital has raised approximately $154 million for its second fund, Monograph Capital Partners II, L.P., which closed in March 2025. The firm actively deploys capital across North America and Europe, focusing on sourcing leading scientific innovations. Monograph Capital has established a strong network within the life sciences sector, facilitating connections with leading scientists and institutions to enhance the development of its portfolio companies.
Notable milestones include the co-founding of several companies alongside scientific innovators, such as Ouro Medicines, which focuses on immune reset therapeutics for chronic autoimmune diseases. Monograph Capital's commitment to improving health outcomes through scientific innovation positions it as a key player in the life sciences venture capital space.
Monograph Capital specializes in early-stage investments within the life sciences sector, with a particular emphasis on therapeutics, diagnostics, and digitally-enabled healthcare. The firm seeks to identify and support companies that are innovating in these areas, aiming to translate scientific advancements into global healthcare solutions. Monograph Capital's investment strategy includes co-founding companies alongside scientists, which allows for a deeper integration of scientific expertise into the business development process.
The firm primarily targets companies across North America and Europe, leveraging its strong connections within the UK and US biotech ecosystems. Monograph Capital looks for founders who demonstrate a clear vision and the capability to execute on innovative ideas. The firm values scientific rigor and a strong understanding of the market landscape, which are critical for the success of early-stage life sciences ventures. Investment check sizes are not publicly disclosed, but the firm is known for leading financing rounds and actively participating in the growth of its portfolio companies.
Monograph Capital's portfolio includes a diverse range of innovative companies in the life sciences sector. Notable portfolio companies include:
This portfolio reflects Monograph Capital's commitment to supporting companies that are at the forefront of scientific innovation in healthcare.
Fred Cohen: Partner and Chairman, MD, DPhil. Fred is a co-founder of Monograph Capital and has previously served as Co-Founder and Senior Managing Director at Vida Ventures. He has extensive experience in healthcare investing and is a registered executive on both Fund I and Fund II SEC filings.
Charles Conn: Partner, MBA, MA. Charles is a co-executive at Monograph Capital and has been involved in both fund filings. His background includes significant experience in venture capital and strategic investments.
Freddie Dear: Principal (Portfolio), BSc. Freddie focuses on portfolio management and has a strong background in life sciences.
Jaideep Dudani: Principal (Portfolio), PhD, BS. Jaideep brings expertise in scientific research and investment analysis to the team.
Tim Funnell: Partner, DPhil, BS. Tim is a co-founder of Monograph and previously co-founded and served as VP of Operations at MiroBio, a Monograph portfolio company.
Melisa Guven: Principal, PhD, MSc, BSc. Melisa contributes her scientific expertise and investment experience to support portfolio companies.
To pitch to Monograph Capital, founders should use the contact email info@monograph.bio or submit through their website at monograph.bio. It is important to include a comprehensive pitch deck that outlines the business model, scientific innovation, and team qualifications. Founders should expect a response within a few weeks, depending on the volume of inquiries.
Warm introductions are preferred, especially from trusted sources within the life sciences community. Monograph Capital values detailed and well-structured pitches that clearly convey the potential impact of the innovation being presented.
In March 2025, Monograph Capital closed its second fund, Monograph Capital Partners II, L.P., raising approximately $154 million. This fund will focus on early-stage investments in life sciences, particularly in therapeutics and diagnostics.
In December 2023, Monograph participated in Series B financing for Sudo, a clinical-stage neuro-immunology company advancing TYK2 inhibitors. This investment reflects Monograph's commitment to supporting innovative healthcare solutions.
In February 2024, Monograph co-led a Series B financing for Nocion Therapeutics, which is developing an inhaled small molecule therapeutic for chronic cough. This investment highlights the firm's focus on addressing unmet medical needs through scientific innovation.
What are Monograph Capital's investment criteria?
Monograph Capital focuses on early-stage life sciences companies, particularly in therapeutics, diagnostics, and digitally-enabled healthcare. The firm seeks innovative companies that can translate scientific advancements into effective treatments.
How can I apply or pitch to Monograph Capital?
Founders can pitch to Monograph Capital via their website at monograph.bio or by emailing info@monograph.bio. It is advisable to include a detailed overview of the business, the team, and the scientific innovation being pursued.
What makes Monograph Capital different from other venture firms?
Monograph Capital combines a unique team of M.D.s and Ph.D.s with extensive healthcare investing experience, allowing them to provide deep scientific insights and strategic guidance to their portfolio companies.
What is the geographic scope of Monograph Capital's investments?
The firm invests primarily in North America and Europe, leveraging its transatlantic team to source opportunities across these regions.
What is Monograph Capital's approach to post-investment involvement?
Monograph Capital actively participates in the development of its portfolio companies, often co-founding ventures alongside scientific innovators and providing strategic guidance and connections within the life sciences sector.
What is the size of Monograph Capital's funds?
Monograph Capital's second fund, Monograph Capital Partners II, L.P., raised approximately $154 million, which closed in March 2025. The size of the first fund has not been publicly disclosed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.